Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

TamPub

Artikkeli aikakauslehdessä

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Julkaisun pysyvä osoite on http://urn.fi/URN:NBN:fi:uta-201709122418

Näytä kaikki kuvailutiedot

Viite kuuluu kokoelmiin: